Burkitt Lymphoma
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.
Drugs by status
Approved for this indication (1)
Phase 4 trials (17)
Phase 3 trials (5)
Phase 2 trials (81)
- allopurinol
- cladribine
- methylprednisolone
- mercaptopurine
- ibritumomab tiuxetan
- acalabrutinib
- allogeneic epstein-barr virus specific cytotoxic t-lymphocytes
- autologous ebv specific cytotoxic t lymphocytes
- venetoclax
- belinostat
- bendamustine
- brentuximab vedotin
- busulfan
- lenalidomide
- temsirolimus
- clofarabine
- polatuzumab vedotin
- n-(4-hydroxyphenyl)all-trans retinamide
- obinutuzumab
- gemcitabine
- oblimersen sodium
- tacrolimus
- hsc835
- hydrocortisone
- beclomethasone
- imexon
- Filgrastim
- nivolumab
- inotuzumab ozogamicin
- ganciclovir
- +51 more
Phase 1 trials (55)
- fau
- decitabine
- dexrazoxane
- alvespimycin
- anti-cd20 b9e9 scfv-streptavidin fusion protein
- autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells
- azd3965
- sorafenib
- blinatumomab
- bryostatin
- irinotecan
- cilengitide
- devimistat
- valproic acid
- eb-vst cells
- entinostat
- paclitaxel
- imatinib
- ar-42
- in111 anti-cd45 monoclonal antibody bc8
- in111-dota-biotin
- ispinesib
- methoxyamine
- morab-004
- msk-2206
- depatuxizumab mafodotin
- sunitinib
- ro4929097
- tanespimycin
- dasatinib
- +25 more
Organizations
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (7)
Organization Involved with Phase 2 Indications (56)
- Seattle Genetics
- Celgene
- Millennium Pharmaceuticals
- Bristol-Myers Squibb
- Amgen
- Roche
- Pharmacyclics
- Genzyme
- Novartis
- The EMMES Corporation
- PETHEMA Foundation
- Medical Research Council
- University of Roma La Sapienza
- University of Pennsylvania
- University of Arizona
- AIDS Malignancy Consortium
- Brown University
- Case Western Reserve University
- Cornell University
- Harvard University
- Duke University
- Emory University
- Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
- University of Washington
- Johns Hopkins University
- New York Medical College
- Northern Italy Leukemia Group
- Northwestern University
- Ohio State University
- Rutgers University
- +26 more
Organization Involved with Phase 1 Indications (22)
- ADC Therapeutics SARL
- Takeda
- Morphotek
- Genentech
- Arno Therapeutics
- Celator Pharmaceuticals
- University of Pittsburgh
- Cancer and Leukemia Group B (CALGB)
- Cancer Research UK
- University of London
- University of Toronto
- Wake Forest University
- Wayne State University
- University of California, Davis
- University of California, San Diego
- University of Cincinnati
- University of Colorado, Denver
- University of North Carolina at Chapel Hill
- University of Wisconsin
- Damon Runyon Cancer Research Foundation
- People's Liberation Army of China
- VelosBio
Organization Involved with Other Experimental Indications (2)